Zoetis (NYSE:ZTS) Lowered to “Buy” at StockNews.com

Zoetis (NYSE:ZTSGet Free Report) was downgraded by stock analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Thursday.

Other equities research analysts have also issued reports about the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $230.00 price objective on shares of Zoetis in a research note on Tuesday, December 19th. BNP Paribas initiated coverage on shares of Zoetis in a research note on Thursday, December 7th. They set an “outperform” rating and a $237.00 target price on the stock. Stifel Nicolaus increased their target price on shares of Zoetis from $195.00 to $215.00 and gave the stock a “buy” rating in a research note on Friday, January 12th. Piper Sandler increased their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, November 6th. Finally, The Goldman Sachs Group increased their target price on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus price target of $223.78.

Read Our Latest Report on ZTS

Zoetis Trading Down 1.9 %

Shares of NYSE ZTS opened at $187.81 on Thursday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.16 and a current ratio of 3.87. Zoetis has a 52-week low of $151.03 and a 52-week high of $201.92. The firm has a 50 day moving average price of $190.65 and a two-hundred day moving average price of $182.29. The stock has a market cap of $86.23 billion, a P/E ratio of 38.17, a price-to-earnings-growth ratio of 2.82 and a beta of 0.85.

Zoetis (NYSE:ZTSGet Free Report) last announced its quarterly earnings results on Thursday, November 2nd. The company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.01. Zoetis had a net margin of 27.24% and a return on equity of 52.22%. The firm had revenue of $2.15 billion during the quarter, compared to analysts’ expectations of $2.17 billion. As a group, equities analysts forecast that Zoetis will post 5.41 EPS for the current year.

Insider Buying and Selling

In related news, CEO Kristin C. Peck sold 13,000 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $176.84, for a total transaction of $2,298,920.00. Following the completion of the sale, the chief executive officer now owns 56,843 shares in the company, valued at $10,052,116.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Kristin C. Peck sold 13,000 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $176.84, for a total transaction of $2,298,920.00. Following the completion of the sale, the chief executive officer now owns 56,843 shares in the company, valued at $10,052,116.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction dated Thursday, January 18th. The stock was sold at an average price of $191.43, for a total transaction of $176,689.89. Following the sale, the executive vice president now owns 17,569 shares of the company’s stock, valued at approximately $3,363,233.67. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,346 shares of company stock worth $3,139,405. Insiders own 0.15% of the company’s stock.

Hedge Funds Weigh In On Zoetis

Large investors have recently modified their holdings of the company. abrdn plc lifted its position in Zoetis by 32.1% during the fourth quarter. abrdn plc now owns 1,025,318 shares of the company’s stock valued at $202,367,000 after purchasing an additional 249,308 shares during the last quarter. J.W. Cole Advisors Inc. lifted its position in Zoetis by 8.3% during the fourth quarter. J.W. Cole Advisors Inc. now owns 1,650 shares of the company’s stock valued at $326,000 after purchasing an additional 127 shares during the last quarter. Beaumont Financial Advisors LLC lifted its position in Zoetis by 8.0% during the fourth quarter. Beaumont Financial Advisors LLC now owns 1,415 shares of the company’s stock valued at $279,000 after purchasing an additional 105 shares during the last quarter. Knights of Columbus Asset Advisors LLC lifted its position in Zoetis by 1.3% during the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 24,416 shares of the company’s stock valued at $4,819,000 after purchasing an additional 316 shares during the last quarter. Finally, Ninepoint Partners LP bought a new stake in Zoetis during the fourth quarter valued at approximately $720,000. 89.47% of the stock is currently owned by institutional investors.

Zoetis Company Profile

(Get Free Report)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Recommended Stories

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.